Search results
Moderna: FDA Extends RSV Vaccine Review, But No Issues Flagged
Market Watch· 6 days agoModerna on Friday said the Food and Drug Administration won't meet its May 12 target action date for a decision on the company's proposed vaccine for respiratory syncytial ...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 19 hours agoIn 2020, the industry was thrust into the pandemic limelight as Pfizer and its partner BioNTech,...
What's Going With Moderna Stock On Friday? - Moderna (NASDAQ:MRNA)
Benzinga· 6 days agoThe Food and Drug Administration (FDA) notified Moderna Inc MRNA on Friday that its review of a new vaccine has been delayed. The agency, citing administrative constraints ...
Moderna to Present at Upcoming Conferences in May/June 2024
Digital Journal· 3 days agoMore from Digital Journal
Moderna says FDA delaying decision on RSV vaccine approval, shares fall By Investing.com
Investing.com· 6 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks...
Moderna’s Promise of mRNA Undercut by New RSV Vaccine
Bloomberg· 7 days agoConnecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly...
Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall By Investing.com
Investing.com· 6 days agoMidday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
Trending: Moderna's Proposed RSV Vaccine Faces Delayed FDA Review
Morningstar· 6 days ago13:53 ET -- Moderna is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The company said that the U.S ...
Post-pandemic problems: These stocks are still down more than 50 percent from their Covid highs
Bankrate via AOL· 18 hours agoIts shares traded as low as $3.55 in December 2022. Covid high stock price: $376.83 Current stock...
Quick takes: Moderna's RSV vaccine, flu-COVID combo vaccines, new polio cases
Center for Infectious Disease Research and Policy· 5 days agoThe FDA has pushed back its review of Moderna's RSV vaccine owing to administrative issues.